Gentaur Pub

#32473573   2020/05/27 To Up

Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives.

The advancements in technology and manufacturing processes have allowed the development of new derivatives, biosimilar or advanced improved versions for approved antibodies each year for treatment regimen. There are more than 700 antibody-based molecules that are in different stages of phase I/II/ III clinical trials targeting new unique targets. To date, approximately more than 80 monoclonal antibodies (mAbs) have been approved. A total of 7 novel antibody therapeutics had been granted the first approval either in the United States or European Union in the year 2019, representing approximately 20% of the total number of approved drugs. Most of these licenced mAbs or their derivatives are either of hybridoma origin or their improvised engineered versions. Even with the recent development of high throughput mAb generation technologies, hybridoma is the most favoured method due to its indigenous nature to preserve natural cognate antibody pairing information and preserves innate functions of immune cells. The recent advent of antibody engineering technology has superseded the species level barriers and has shown success in isolation of hybridoma across phylogenetically distinct species. This has led to the isolation of monoclonal antibodies against human targets that are conserved and non-immunogenic in the rodent. In this review, we have discussed in detail about hybridoma technology, its expansion towards different animal species, the importance of antibodies isolated from different animal sources that are useful in biological applications, advantages, and limitations. This review also summarizes the challenges and recent progress associated with hybridoma development, and how it has been overcome in these years to provide new insights for the isolation of mAbs.
Hilal Ahmed Parray, Shivangi Shukla, Sweety Samal, Tripti Shrivastava, Shubbir Ahmed, Chandresh Sharma, Rajesh Kumar

1726 related Products with: Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives.

25 µg100 TESTS100 ul Product tipe: Anti0.2 mg25 µg0.25 mg1 ml0.2 mg200.00 ug100.00 ug100.00 ug200 ug

Related Pathways

#32473415   2020/04/19 To Up

Evaluation of the Dual Path Platform (DPP) VetTB assay for the detection of Mycobacterium bovis infection in badgers.

Bovine tuberculosis (bTB), caused by Mycobacterium bovis, represents a major animal health issue. In the United Kingdom and the Republic of Ireland, European badgers (Meles meles) have been shown to act as a reservoir of M. bovis infection, hindering the eradication of bTB in livestock. The availability of suitable diagnostic assays, particularly those that may be applied in a "trap-side" setting, would facilitate the implementation of a wider range of disease control strategies. Here we evaluate the Dual Path Platform (DPP) VetTB assay, a lateral-flow type test for detecting antibodies to M. bovis antigens (MPB83 and ESAT-6/CFP-10). Both serum and whole blood were evaluated as diagnostic samples. Additionally, two methods were evaluated for interpretation of test results (qualitative interpretation by eye and quantitative measurement using an optical reader). The antibody response to MPB83 detected by the DPP VetTB assay increased significantly following experimental M. bovis infection of badgers, whilst the response to ESAT-6/CFP-10 showed no significant change. In sera from TB-free captive and naturally M. bovis infected wild badgers the MPB83 response exhibited a sensitivity of 55 % by eye and quantitative reader (95 % CI: 40-71 and 38-71, respectively), with slightly lower specificity when read by eye (93 % compared to 98 %; 95 % CI: 85-100 and 90-100, respectively). In whole blood, the DPP VetTB assay MPB83 response exhibited a sensitivity of 65 % (95 % CI: 50-80) when interpreted by eye and 53 % (95 % CI: 36-69) using quantitative values, whilst the specificity was 94 % and 98 % respectively (95 % CI: 88-100 and 90-100). Comparison with contemporaneous diagnostic test results from putatively naturally infected and TB-free badgers demonstrated varying levels of agreement. Using sera from naturally M. bovis infected and TB-free badgers, with post mortem confirmation of disease status, the DPP VetTB assay exhibited a sensitivity of 60 % (95 % CI: 41-77) when interpreted using quantitative values (specificity 95 %; 95 % CI: 76-100), and 67 % (95 % CI: 50-84) when read by eye (specificity 95 %; 95 % CI: 86-100). Further work is required to robustly characterize the DPP VetTB assay's performance in a wider selection of samples, and in the practical and epidemiological contexts in which it may be applied.
Roland T Ashford, Paul Anderson, Laura Waring, Dipesh Davé, Freya Smith, Richard J Delahay, Eamonn Gormley, Mark A Chambers, Jason Sawyer, Sandrine Lesellier

2529 related Products with: Evaluation of the Dual Path Platform (DPP) VetTB assay for the detection of Mycobacterium bovis infection in badgers.

1

Related Pathways

#32473290   2020/05/27 To Up

Sortase-A mediated chemoenzymatic lipidation of single-domain antibodies for cell membrane engineering.

Membrane engineering has versatile applications in adoptive cell therapies, immune therapy or drug delivery. Incorporation of lipidated antibody-derived ligands into cells may enforce supraphysiological cell interactions that offer new therapeutic approaches. A challenge is the defined synthesis of lipidated ligands that effectively interact with such membranes.
Steffen Wöll, Christopher Bachran, Stefan Schiller, Lee Kim Swee, Regina Scherließ

2688 related Products with: Sortase-A mediated chemoenzymatic lipidation of single-domain antibodies for cell membrane engineering.

1 mg4 Membranes/Box4 Membranes/Box2 Pieces/Box200 50 mg0.5 ml100 μg1 mL4 Membranes/Box0.1 mg1 mL

Related Pathways

#32473188   2020/05/27 To Up

Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge.

Despite the increasing trend towards subcutaneous delivery of monoclonal antibodies, factors influencing the subcutaneous bioavailability of these molecules remain poorly understood. To address critical knowledge gaps and issues during development of subcutaneous dosage forms for monoclonal antibodies, the Subcutaneous Drug Delivery and Development Consortium was convened in 2018 as a pre-competitive collaboration of recognized industry experts. One of the Consortium's eight problem statements highlights the challenges of predicting human bioavailability of subcutaneously administered monoclonal antibodies due to a lack of reliable in vitro and preclinical in vivo predictive models. In this paper, we assess the current landscape in subcutaneous bioavailability prediction for monoclonal antibodies and discuss the gaps and opportunities associated with bioavailability models for biotherapeutics. We also issue an open challenge to industry and academia, encouraging the development of reliable models to enable subcutaneous bioavailability prediction of therapeutic large molecules in humans and improve translation from preclinical species.
Manuel Sánchez-Félix, Matt Burke, Hunter H Chen, Claire Patterson, Sachin Mittal

1735 related Products with: Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge.

100.00 ug200 ug1 mg100.00 ug100.00 ug100 ug1 mg200 ug100.00 ug100.00 ug1 mg1 mg

Related Pathways

#32473178   2020/05/27 To Up

Efficiently restoring the tumoricidal immunity against resistant malignancies via an immune nanomodulator.

Bioinformatically triple negative breast cancer (TNBC) and colon adenocarcinoma (COAD), two typical "cold" cancers, were found overexpressed PD-L1 and CD47 respectively but neither of them showed satisfied response on its corresponding immune checkpoint blockade (ICB) in clinic. The initial immunotherapeutic resistance to ICB was essentially attributed to the so-called "cold" tumor immune milieu (TIM). To overcome tumor immunological tolerance against ICBs, here we report a versatile nano-modulator for point-to-point counteracting the immune-suppressors meanwhile boosting tumor T cell infiltration. Small interfering RNA targeting indoleamine 2,3-dioxygenase-1 was first co-delivered with gemcitabine using our lab-made biocompatible nanocages for relieving the immune brakes related to regulatory T cells and myeloid-derived suppressor cells. O-producible mineralization was then tattooed on the surface of the nanocarriers to alleviate the immune inhibition of M2 macrophages. Followed with the decoration of therapeutic ICB antibodies on the mineralized shell, a versatile nano-modulator was constructed. TNBC and COAD were employed to evaluate the tumoricidal efficacy of the nano-modulator that decorated with aPD-L1 and aCD47, respectively. Our nano-modulator demonstrated multipotencies in eliciting a "hot" TIM and greatly potentiated ICB treatment for these "cold" malignancies. The strung expansibility of the nano-modulator may be also conducive in addressing the failure of more other ICBs on the non-responsive subpopulation of patients despite the corresponding immune checkpoint highly expressed in tumors.
Chen Chen, Aning Li, Peng Sun, Jiawen Xu, Wei Du, Jing Zhang, Ying Liu, Rui Zhang, Shengchang Zhang, Zhenmei Yang, Chunwei Tang, Xinyi Jiang

2776 related Products with: Efficiently restoring the tumoricidal immunity against resistant malignancies via an immune nanomodulator.

100ug/vial100 ug/vial100 ug/vial0.1 mg1 ml100ug/vial100ug/vial100ug/vial100 ug/vial

Related Pathways

#32473121   2020/05/27 To Up

Mitochondrial DNA methylation misleads global DNA methylation detected by antibody-based methods.

C
, , , ,

2618 related Products with: Mitochondrial DNA methylation misleads global DNA methylation detected by antibody-based methods.

96 assays 100ul100ug Lyophilized100ug100ug100ug Lyophilized100ug100ug Lyophilized100ug100ug Lyophilized

Related Pathways

No related Items

#32473038   2020/05/30 To Up

TLR3 ligation affects differentiation and stemness properties of gingival mesenchymal stem/progenitor cells.

Toll-like-receptors are key players in mesenchymal stem/progenitor cells' micro-environmental crosstalk, endorsing various biological reactions. For the first, time this study investigates the effects of TLR3-ligation on gingival mesenchymal stem/progenitor cells (G-MSCs) stemness and differentiation properties.
Mohamed Mekhemar, Johannes Tölle, Christof Dörfer, Karim Fawzy El-Sayed

1741 related Products with: TLR3 ligation affects differentiation and stemness properties of gingival mesenchymal stem/progenitor cells.

5 x 10A5 cells/vial24 wells24 wells1 vial1 mg0.1ml (1mg/ml)10 ug1 x 10^6 cells/vial5 x 50 ug50 ug24 wells1.00 flask

Related Pathways

Error loading info... Pleas try again later.

Error loading info... Pleas try again later.

Error loading info... Pleas try again later.